 Nes-Ziona, Israel, Feb. 26, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain institutional investors of 1,000,000 ordinary shares of the Company at a purchase price of 8.00 per share for aggregate gross proceeds of 8.0 million. The Company intends to use the net proceeds from the offering for clinical, regulatory, manufacturing and research and development activities, potential acquisitions and in-licensing, as well as for working capital and other general corporate purposes. A shelf registration statement on Form F-3 File No. 333-232009 relating to the ordinary shares offered in the registered direct offering was filed with the Securities and Exchange Commission the SEC on June 7, 2019 and declared effective by the SEC on June 21, 2019. 